Since the approval of the high-sensitivity cardiac troponin-T (hs-cTnT) assay by the US Food and Drug Administration in 2017 for clinical care, there has been renewed interest in determining blood concentrations in individuals without acute myocardial infarctions (AMI) [1, 2]. The gene discussed is TNNT2; the disease is myocardial infarction.